Response to ‘Renal microvascular and tubular injuries in type II diabetic nephropathy’  by Verzola, Daniela et al.
In this study, we have actually used calcidiol, which
increased serum 25 OH vitamin D levels from 10 to 30 ng/ml
and those of calcitriol from 84 to 100 pmol/L. In addition
1.2 g/day of elemental calcium was given as CaCO3 for
phosphate binding. C-terminal parathyroid hormone levels
stabilized for 18 months in spite of a glomerular filtration
rate decline from 25 to 15 ml/min, suggesting a decrease
in parathyroid hormone secretion. Hyperparathyroidism
suppression was furthermore evidenced by a decrease of
alkaline phosphatase and bone remodeling parameters.
Meanwhile, two cohort studies of 40 young adults with
childhood-onset end-stage renal disease have been reported,
which documented a coronary calcification prevalence of
92% in Heidelberg and 10% in Berlin, although biographical
and therapeutical characteristics were comparable at the
exception of vitamin D therapy that was based in Heidelberg
mainly on 1aOH vitamin D (eightfolds greater yearly dose),
whereas in Berlin, it was based on 5750 IU/day of vitamin D3,
a dose which according to Garabedian yielded approximately
60 ng/ml of serum calcidiol.3
Therefore, we would like to propose that in predialysis
as in dialysis patients, activated vitamin D be evaluated against
placebo provided plain or 25 OH vitamin D3 has first stabi-
lized their 25 OH vitamin D serum levels at 40±10 ng/ml.
1. Levin A, Bakris GL, Molitch M et al. Prevalence of abnormal serum
vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney
disease: results of the study to evaluate early kidney disease. Kidney Int
2007; 71: 31–38.
2. Fournier A, Idrissi A, Sebert JL et al. Preventing renal bone disease in
moderate renal failure with CaCO3 and 25(OH) vitamin D3. Kidney Int
Suppl 1988; 24: S178–S179.
3. Fournier A, Harbouche L, Mansour J et al. Impact of calcium and
vitamin D therapy on arterial and cardiac disease in young adults with
childhood-onset end stage renal disease. Nephrol Dial Transplant 2007;
22: 956–957; author reply 957–958.
Mervet Rouached1, Sarra El Kadiri Boutchich1, Assem Mohamed
Al Rifai1, Miche`le Garabe´dian2 and Albert Fournier1
1Nephrology Department CHU, Amiens, France and 2Laboratoire des Tissus
Calcifie´s—CNRS St Vincent de Paul, Paris, France
Correspondence: Albert Fournier, Department of Nephrology, Hospital Sud,
Avenue Rene Laennec, Amiens 80054, France.
E-mail: Fournier.Albert@chu-amiens.fr
Renal microvascular and tubular
injuries in type II diabetic
nephropathy
Kidney International (2008) 74, 390; doi:10.1038/ki.2008.173
To the Editor: We read Verzola et al.’s1 article with great
interest. The authors have pointed out the significance of
glomerular cell injury and a correlation between the renal
microvascular injury and the magnitude of tubulointerstitial
fibrosis in type II diabetic nephropathy. Such correlation is
further supported by recent intrarenal hemodynamic study,
which reveals a phenomenon the so-called hemodynamic
maladjustment secondary to glomerular endothelial cell
dysfunction, which is characterized by a preferential con-
striction of the efferent arteriole, and a subsequent reduction
in peritubular capillary flow inducing a chronic ischemic
injury to the tubulointerstitium.2 The peritubular capillary
flow reduction correlates inversely with the magnitude of
tubulointerstitial fibrosis, and it progressively decreases as the
disease severity increases from normoalbuminuric to albu-
minuric type II diabetic nephropathy. Thus, renal micro-
vascular injury has a significant impact on renal disease
progression. In this regard, it is mandatory to recognize renal
microvascular disease at an early stage of type II diabetic
nephropathy in which the mechanism of vascular repair is
still adequately maintained,3 and treatment at this early stage
under favourable environment is capable of restoring renal
perfusion and function.4 To accomplish an effective pre-
ventive strategy of renal disease progression in type II diabetic
nephropathy, it would require a more sensitive diagnostic
marker than microalbuminuria, such as fractional excretion
of magnesium, to screen early stage of diabetic nephropathy.5
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We thank Drs Narisa and Prasit Futrakul for their interest
in our paper.1 The findings observed in their studies,
implying a maladaptive constriction of the efferent
arteriole and downstream vascular and tubulointerstitial
damage in type II diabetic patients, are appealing.2 One
of the basic abnormalities in diabetic nephropathy is
microalbuminuria, which eventually progresses to protein-
uria. Downstream into the tubular compartment, the
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proteinuria induces a proinflammatory injury in tubular
cells, which can ease the development of interstitial fibrosis
and tubular atrophy.3 However, at variance with type I
diabetic patients, a considerable number of type II diabetic
patients, even with microalbuminuria or macroalbumin-
uria, have normal glomerular structure but show tubulo-
interstitial and/or arteriolar abnormalities.4 In type II
diabetes, hyperglycemia5 and hypertension6 may cooperate
to impair the physiologic mechanism that main-
tains normal glomerular capillary pressure and tubular
function.6,7
In our study, we evaluated apoptosis in renal biopsies
obtained from patients with early or advanced type II
diabetic nephropathy. We found that apoptotic changes
are diffusely increased in glomeruli, tubuli, and vascular
endothelia. According to our findings, apoptotic cell loss
is already observed in proteinuric patients with normal
or subnormal glomerular filtration rate and only modest
biopsy changes, suggesting that the acceleration of
apoptotic processes is an early phenomenon, Thus, besides
being a pathogenic mechanism of cell loss, apoptosis
can also be an additional tool for the evaluation of early
kidney damage. In patients with more advanced disease,
glomerular apoptosis is directly related to the histological
scores of glomerular sclerosis, mesangial proliferation, and
tubule atrophy.
Low serum magnesium level is an independent pre-
dictor of incident type II diabetes.8 In addition, hypo-
magnesemia has been linked to poor glycemic control and
diabetes complication.9 We did not study kidney magne-
sium handling in our patients. However, the observation
by Futrakul is interesting, as the increased incidence
of hypomagnesemia among patients with type II diabetes
has so far been considered multifactorial.9 We agree with
their suggestions in studying the function of kidney tubule
in patients with type II diabetes mellitus, as a clue for
the occurrence of early microvascular damage. Further
exploration of both the biology of renal cells and the
mechanisms of diabetic disease will be critical for
developing new preventive, diagnostic and therapeutic
approaches to diabetic nephropathy.
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To the Editor: I sincerely congratulate Fervenza et al.1
on their paper describing the effect of rituximab in idiopathic
membranous nephropathy. In fact, I believe that their results
might allow for a more optimistic assessment. Plotting from
their Table 2, the proteinuria over the time from 6 months
before treatment and until 12 months after treatment very
clearly shows that nothing happens under the 6-month
observation, but a clear course then develops afterward that
does not end at 12 months. To show that, it is helpful to use a
log-transformed proteinuria. Figure 1 indicates that the
chosen method of analysis, a paired t-test based on the
baseline to 12 months difference, is conservative and uses less
information than is, in fact, available.
To analyze the figure, a linear mixed model,2 with
intercepts and slopes modeled (‘random’), was made from
the reported data using the freely available R.3 It was found
that both time (t¼3.45, P¼ 0.0008) and creatinine
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Figure 1 | Longitudinal effect of Rituximab on proteinuria
(log transformed).
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